Alcon AG is a leading global medical company specializing in eye care products and technologies. It was founded in 1945 by pharmacists Robert Alexander and William Conner as a small ophthalmic pharmaceutical company in Fort Worth, Texas. Over the years, Alcon expanded its portfolio and presence to become a major player in the eye care industry.
Alcon's primary focus is on providing a wide range of eye care solutions, including surgical equipment, pharmaceuticals, and contact lenses. The company is known for its innovation in areas such as cataract surgery, glaucoma treatment, and refractive surgery. Alcon's products are used by eye care professionals worldwide to diagnose, treat, and manage various eye conditions.
In 2019, Alcon became an independent company through a spin-off from Novartis, its former parent company. It is now listed on the SIX Swiss Exchange under the ticker symbol "ALC" and on the New York Stock Exchange (NYSE) under the same symbol. This dual listing allows investors to trade Alcon's shares on both Swiss and U.S. stock exchanges.
Alcon's commitment to research and development drives its ability to introduce new and innovative eye care solutions. The company's advancements in technology have played a significant role in improving patients' quality of life by enhancing their vision and treating eye conditions more effectively. With a global presence in over 140 countries, Alcon is dedicated to providing eye care professionals with the tools they need to help patients maintain healthy eyesight.